ライフサイエンスコーパス: molecular imaging

1 A-positive tumor phenotypes were selected by molecular imaging.

2 of imaging agent used for both anatomic and molecular imaging.

3 ntrast agents that could be used for in vivo molecular imaging.

4 ainst HER2 have been developed as probes for molecular imaging.

5 iolabeling of chelator-modified peptides for molecular imaging.

6 ctrometry (IMS) is a maturating technique of molecular imaging.

7 d attention as probes for radionuclide-based molecular imaging.

8 pplications such as blood pool, cellular and molecular imaging.

9 demonstrate the feasibility of PSMA-based MR molecular imaging.

10 ecules represent an interesting platform for molecular imaging.

11 d serve as a suitable biomarker for MR-based molecular imaging.

12 lds of radiochemistry, nuclear medicine, and molecular imaging.

13 s targeting ligands and their application in molecular imaging.

14 ate cancer and is being used as a target for molecular imaging.

15 properties that make them uniquely suited to molecular imaging.

16 s a promising new platform for multimodality molecular imaging.

17 and future cancer biomarker applications of molecular imaging.

18 electivity and sensitivity for multimodality molecular imaging.

19 g, cell tracing, inflammation monitoring and molecular imaging.

20 the theranostic application of fluorescence molecular imaging.

21 lectrons are shown to be a powerful tool for molecular imaging.

22 alidated as a clinically relevant target for molecular imaging.

23 in human embryonic stem cells for long-term molecular imaging.

24 vides a tool for spectroscopic photoacoustic molecular imaging.

25 ke it an attractive nuclide for labeling and molecular imaging.

26 f these new organic nanoparticles in in vivo molecular imaging.

27 An elastin-specific magnetic resonance molecular imaging agent (ESMA) was administered after 1,

28 OTA lipid bilayer, as a targeting multimodal molecular imaging agent for magnetic resonance and optic

29 injection and imaging of a positron-emitting molecular imaging agent into the submucosa of the porcin

30 as to assess (18)F-AH113804, a peptide-based molecular imaging agent with high affinity for human c-M

31 SLNs after administration of a dual-labeled molecular imaging agent.

32 Early detection of recurrence by molecular imaging agents against therapeutically targeta

33 Molecular imaging agents for preoperative positron emiss

34 Despite promise for the use of antibodies as molecular imaging agents in PET, their long in vivo half

35 s have been successfully designed for use as molecular imaging agents to investigate carbohydrate-lec

36 horesis, and for their suitability to become molecular imaging agents, using fluorescence spectroscop

37 odistribution behavior of submicron-diameter molecular imaging agents.

38 ry and validation of anticancer therapies or molecular imaging agents.

39 Molecular imaging allows the noninvasive assessment of c

40 Noninvasive molecular imaging allows whole-body metabolic characteri

41 Molecular imaging also plays increasingly important role

42 sassembly of small molecules, especially for molecular imaging and anticancer therapeutics.

43 eceptor to identify promising candidates for molecular imaging and Auger electron-based radionuclide

44 Here, we used a combination of molecular imaging and biochemical tools to study the pro

45 or in vivo targeting applications, including molecular imaging and cell tracking.

46 capabilities provide a powerful platform for molecular imaging and characterization of tissue noninva

47 le new uses of ultrasound contrast agents in molecular imaging and drug delivery, particularly for ca

48 tures for biological applications, including molecular imaging and drug delivery.

49 Sophisticated diagnostics, including molecular imaging and genomic expression profiles, enabl

50 /MR offers new tools with an exact fusion of molecular imaging and high-resolution anatomic imaging.

51 endocrine tumors, is a well-known target for molecular imaging and peptide receptor radionuclide ther

52 ymporter (hNIS) is an established target for molecular imaging and radionuclide therapy.

53 These contrast agents are used for ultrafast molecular imaging and spectroscopy at 4.7 and 0.0475 T.

54 The Society of Nuclear Medicine and Molecular Imaging and the American College of Nuclear Me

55 ant with the Society of Nuclear Medicine and Molecular Imaging and the European Association of Nuclea

56 and technology-and the practice of clinical molecular imaging and theranostics-has created a need fo

57 es and selectively bind tissues for targeted molecular imaging and therapeutic delivery.

58 have been widely applied in the research of molecular imaging and therapy.

59 tate cancer (PCa) and a promising target for molecular imaging and therapy.

60 The molecular imaging and treatment of neuroendocrine tumors

61 ture, offering possibilities for ultrasound (molecular) imaging and targeted therapies.

62 MNCs) and mouse hearts using immunoblotting, molecular imaging, and [(35)S]methionine pulse-chase exp

63 eeds for the modern practice of NM, clinical molecular imaging, and radionuclide therapy; and suggest

64 dependent handles in targeted drug delivery, molecular imaging, and therapeutic drug monitoring.

65 Here, we used combined molecular, imaging, and anatomical approaches to investi

66 plied as the xenon MRI field moves closer to molecular imaging applications in vivo.

67 articularly the limitations, of quantitative molecular imaging applications.

68 ing suitability of these species for in vivo molecular imaging applications.

69 This highly sensitive optical molecular imaging approach can profoundly impact a wide

70 We report a molecular imaging approach to quantitate protein levels

71 In summary, a multimodal molecular imaging approach was used to identify the drug

72 The molecular imaging approach we developed could be transla

73 nt methods, as well as review functional and molecular imaging approaches being investigated as emerg

74 Molecular imaging approaches can detect and quantify the

75 This review will examine how novel molecular imaging approaches can provide such assessment

76 Multitracer and multimodal molecular imaging approaches may allow us to gain import

77 Consequently, molecular imaging approaches may be used in patients to

78 To this end, molecular imaging approaches using neurotransmitter-sens

79 nd semiautomatic contouring methods based on molecular imaging are available but still need sufficien

80 The newest developments in molecular imaging are described, and methods are compare

81 four major interventional opportunities for molecular imaging are, first, to provide guidance to loc

82 This "Focus on Molecular Imaging" article reviews the current role of b

83 ailable literature and the current status of molecular imaging as a tool for the assessment of HER2 (

84 ept for the use of B7-H3-targeted ultrasound molecular imaging as a tool to improve the diagnostic ac

85 formal radiotherapy (dose painting) based on molecular imaging-assessed tumor heterogeneity is being

86 maging (PAI) has the potential for real-time molecular imaging at high resolution and deep inside the

87 Using in vivo molecular imaging at various stages of atherosclerosis,

88 ittee of the Society of Nuclear Medicine and Molecular Imaging, based on 2007 recommendations of the

89 DAPT) is a promising tracer for radionuclide molecular imaging because of its small size (6.5 kDa), w

90 articles are not always the right choice for molecular imaging (because smaller or larger molecules m

91 As molecular imaging better delineates the state of prostat

92 The development and validation of novel molecular imaging biomarkers has the potential to improv

93 developments on the horizon, such as the new molecular imaging biomarkers under investigation that ca

94 We used noninvasive molecular imaging (blood oxygen level-dependent magnetic

95 Gel permeation chromatography analysis and molecular imaging by atomic force microscopy confirmed t

96 inescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by (18)F-FD

97 The development of molecular imaging by MRI requires the use of contrast ag

98 68 min) that is particularly well suited for molecular imaging by positron emission tomography (PET).

99 ams is necessary, as optimal and safe use of molecular imaging can be ensured only within appropriate

100 MR molecular imaging can combine the high spatial resolutio

101 Contrast-enhanced ultrasound molecular imaging can detect endothelial inflammation an

102 radiation oncology, the greatest impact that molecular imaging can have may be in the reduction of in

103 Molecular imaging can provide an early noninvasive pheno

104 Observations: Molecular imaging can provide unique information to guid

105 We reported previously that molecular imaging classification of early dementia and M

106 This review highlights current metabolic and molecular imaging clinical and near-clinical application

107 ogram of the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network.

108 Metabolic and molecular imaging continues to advance our understanding

109 y and cellular responses, if acquired with a molecular imaging contrast agent.

110 xpanded over the years with the emergence of molecular imaging contrast agents specifically targeted

111 ork for the eventual clinical translation of molecular imaging contrast agents.

112 Molecular imaging could be used to monitor therapy respo

113 pothesized that contrast-enhanced ultrasound molecular imaging could detect myocardial inflammation a

114 The quantification of pulmonary molecular imaging data remains challenging because of va

115 Molecular imaging data were compared with follow-up gado

116 A handheld optical molecular imaging device was constructed to pass through

117 The custom-designed molecular imaging device, in combination with ICG, readi

118 variety of applications such as biosensing, molecular imaging, drug delivery and tissue engineering.

119 cine, but plays a surprisingly small role in molecular imaging due to a lack of suitable molecular re

120 Three-dimensional (3D) molecular imaging enables the study of biological proces

121 gate the feasibility of in vivo MMP-targeted molecular imaging for detection of lung inflammation and

122 e feasibility and correlates of MMP-targeted molecular imaging for detection of valvular biology in C

123 volume and organ-at-risk delineation, use of molecular imaging for tumor delineation, dose painting f

124 By integrating molecular imaging functionalities into therapy, theranos

125 ic motility; Society of Nuclear Medicine and Molecular Imaging guidelines are predicated on imaging o

126 g to current Society of Nuclear Medicine and Molecular Imaging guidelines, served as the gold standar

127 elied on assays of blood or tissue; however, molecular imaging has a promising and complementary role

128 Molecular imaging has a promising role in complementing

129 Functional and molecular imaging has become increasingly used to evalua

130 n dopaminergic transmission in this disease, molecular imaging has been used to examine multiple aspe

131 Although molecular imaging has had a dramatic impact on diagnosti

132 Molecular imaging has potential in this regard; however,

133 Advances in preclinical molecular imaging have generated new opportunities to no

134 Molecular imaging holds considerable promise for elucida

135 Molecular imaging holds great promise for precision onco

136 Optical molecular imaging holds the potential to improve cancer

137 , and 62.5 mg/m(2)), we show that by optical molecular imaging (i.e. denominated as In vivo Fluoresce

138 To determine if intraoperative molecular imaging (IMI) can improve detection of maligna

139 crobial colonies requires their non-targeted molecular imaging in a native environment.

140 s for OCT imaging, noninvasive and real-time molecular imaging in both living and nonviable systems a

141 ude with a perspective on the future role of molecular imaging in defining safety and efficacy for cl

142 amer-based activatable PA probe for advanced molecular imaging in living mice.

143 Thus far, most trials of novel molecular imaging in oncology have been small, single-ce

144 With the increasing presence of molecular imaging in radiation oncology, special emphasi

145 current results demonstrate that microscale molecular imaging in vivo is already feasible at low (<5

146 all molecule analytes for in vitro assays or molecular imaging in vivo.

147 for more multidisciplinarity in the field of molecular imaging, in which close interaction and traini

148 We demonstrate several mechanisms for molecular imaging, including intrinsically expressed GFP

149 s in which managing clinicians would welcome molecular imaging innovations to help with decision maki

150 lds significant promise for the expansion of molecular imaging into the realm of interventional proce

151 Molecular imaging is a complementary approach that provi

152 nature of nuclear medicine (NM) and clinical molecular imaging is a key strength of the specialty, th

153 While the use of bioluminescent proteins for molecular imaging is a powerful technology to further ou

154 Although molecular imaging is already strongly embedded in radiot

155 Photoacoustic molecular imaging is an emerging and promising diagnosti

156 Molecular imaging is an important advancement that has b

157 Biomarker-driven molecular imaging is complementary to pathologic analysi

158 The potential of using nanoparticles for molecular imaging is compromised because their pharmacok

159 Molecular imaging is indispensable for determining the f

160 y to avail high-resolution structural and/or molecular imaging is particularly glaring, leading to a

161 Here, we show that such discrete molecular imaging is possible using DNA-PAINT (points ac

162 ure and quantitative end point obtainable by molecular imaging, it seems inherently suited for the ex

163 We assessed S100A9 as a molecular imaging marker for the activity of tumor-assoc

164 years, there has been a growing interest in molecular imaging markers of tumor-induced angiogenesis.

165 ne whether an intraoperative optical biopsy (molecular imaging) may provide an alternative approach f

166 Observations: Molecular imaging methods and magnetic resonance imaging

167 Highly sensitive and specific non-invasive molecular imaging methods are particularly desirable for

168 t offers several major advantages over other molecular imaging methods.

169 (18)F-FDG PET/CT remains the main molecular imaging modality in radiation oncology applica

170 e towards using the HyperCEST technique as a molecular imaging modality.

171 Molecular imaging, most especially PET, can therefore be

172 Therefore, a multi-modal molecular imaging (MRI & MALDI IMS) approach was employe

173 and evaluate a new radiotracer (18)F-IRS for molecular imaging mutant EGF Receptors in vitro and vivo

174 er nanoparticles (SPNs) emerge as attractive molecular imaging nanoagents in living animals because o

175 Herein, we report molecular imaging of a rat model of hepatic IR with the

176 he vessel wall and its proximity with blood, molecular imaging of aneurysm optimally requires highly

177 Thus, functional and molecular imaging of angiogenesis can be performed with

178 widely used clinical tool for metabolic and molecular imaging of atherosclerosis.

179 Molecular imaging of biological processes associated wit

180 three distinct biomedical applications: (a) molecular imaging of blood vessels, (b) tracking of nano

181 Molecular imaging of cancer biomarkers is critical for n

182 Molecular imaging of cell death may provide a detailed r

183 Adoption of molecular imaging of coronary plaque into clinical pract

184 4 (CXCR4) represents a promising target for molecular imaging of different CXCR4-positive cell types

185 ustic contrast agents are highly desired for molecular imaging of diseases, especially for deep tumor

186 Molecular imaging of ECM may help understand pathology,

187 porous silicon (pSi) is a key technique for molecular imaging of exogenous and endogenous low molecu

188 Molecular imaging of granzyme B activity can visualize T

189 If validated in humans, molecular imaging of inflammation and remodeling can pot

190 Our results show that noninvasive molecular imaging of innate immune responses can serve a

191 applications such as blood pool imaging and molecular imaging of ischemia, angiogenesis, atheroscler

192 800 cm(-1) ) is highly required for specific molecular imaging of living cells with high spatial reso

193 useful as a potential contrast agent for the molecular imaging of metabolism and other applications.

194 Dual molecular imaging of myocardial ischemia/reperfusion inj

195 Molecular imaging of nanoparticle deposition may help to

196 Such approaches offer promise in the molecular imaging of neurotransmission in the brain, usi

197 formative survey of the current state of the molecular imaging of ovarian cancer.

198 P-1 analogs have demonstrated a potential in molecular imaging of pancreatic beta-cells; this may be

199 Targeted molecular imaging of PARP using fluorescent or radiolabe

200 nce precision cancer medicine facilitated by molecular imaging of preclinical breast cancer models ar

201 atients, making it an interesting target for molecular imaging of RA.

202 l coherence tomography (VIS-OCT) for in vivo molecular imaging of rhodopsin.

203 Non-invasive molecular imaging of systemic amyloid is performed in Eu

204 In this review, we will focus on molecular imaging of the AR-axis in metastatic CRPC (mCR

205 Contrast-enhanced ultrasound molecular imaging of the heart was performed.

206 T) is a powerful analytical tool for in vivo molecular imaging of the human brain.

207 Accordingly, molecular imaging of the MMP-12 active form can inform o

208 Platelet-targeted contrast ultrasound molecular imaging of the thoracic aorta performed with m

209 We demonstrated that FBP7 is suitable for molecular imaging of thrombosis and thrombolysis in vivo

210 hrombi and represents an ideal candidate for molecular imaging of thrombosis.

211 , and promising developments in, the in vivo molecular imaging of tumor immune components designed to

212 The CH1055 dye also allowed targeted molecular imaging of tumours in vivo when conjugated wit

213 rgeting of activated platelets may allow for molecular imaging of vulnerable atherosclerotic lesions.

214 Although other molecular imaging options (e.g., proliferation imaging)

215 d genetically encoded reporters suitable for molecular imaging or cell tracking.

216 Changes in functional and molecular imaging parameters after IC1 were compared bet

217 tween the IC1 and IC2 for all functional and molecular imaging parameters, indicating that most biolo

218 Molecular imaging plays a central role in the management

219 Molecular imaging plays an important role in detection a

220 not only provide a ratiometric photoacoustic molecular imaging probe for the detection of metal ions

221 Here we review the development of novel molecular imaging probes and combinations of probes to g

222 d in mice using fluorine-18 labelled glucose molecular imaging probes and non-invasive positron emiss

223 ghly two-thirds of the body, but delivery of molecular imaging probes to these spaces can be challeng

224 B and hold promise as a platform to develop molecular imaging probes.

225 st antibody-based fragments possessing ideal molecular imaging properties, such as high target specif

226 ith in vivo inflammatory changes detected at molecular imaging (r = 0.64, P = .0099).

227 Near-infrared fluorescence molecular imaging revealed a significant reduction in ca

228 Molecular imaging revealed intense lung inflammation coi

229 In this "Focus on Molecular Imaging" review, we seek to provide a brief ye

230 Molecular imaging showed increased calcium signal intens

231 In contrast, contrast-enhanced ultrasound molecular imaging showed increased signals for all targe

232 liminated platelet and von Willebrand factor molecular imaging signal.

233 (CTN) of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) operates a PET/CT phantom imag

234 age-Guided Surgery, and members of the World Molecular Imaging Society, which discussed consensus met

235 FDG-PET/CT may offer a molecular imaging strategy to accurately diagnose recurr

236 receptor (PRLR), forming the basis of a new molecular imaging strategy.

237 rlooked prerequisite to successfully perform molecular imaging studies in vivo by PET.

238 cological, functional magnetic resonance and molecular imaging studies of dopamine function in bipola

239 may, thus, also be important for XFEL-based molecular imaging studies.

240 Advanced molecular imaging, such as iron oxide nanoparticle imagi

241 We therefore used sensitive molecular imaging, supported by multiple independent ana

242 ates the potential of (15) N2 -diazirines as molecular imaging tags for biomedical applications.

243 echanisms and potential myocardial viability molecular imaging targets in acute and chronic ischemia,

244 mitting radionuclides can be exploited for a molecular imaging technique known as Cerenkov luminescen

245 compared with MRI in the acute setting, this molecular imaging technique may be better positioned as

246 ass spectrometry imaging (MSI) is a powerful molecular imaging technique.

247 his focus review describes the metabolic and molecular imaging techniques currently available for cli

248 New magnetic resonance (MR) molecular imaging techniques offer the potential for non

249 Advanced structural and molecular imaging techniques offer the potential to iden

250 Noninvasive molecular imaging techniques, such as SPECT and PET, pro

251 ods and the innovation of new functional and molecular imaging techniques.

252 Developments in molecular imaging technologies and percutaneous biopsy t

253 potentials of alphavbeta3 integrin-targeted molecular imaging technologies for detection of PDAC usi

254 s to place luminescence-based interventional molecular imaging technologies into perspective to the a

255 Purpose To evaluate whether noninvasive molecular imaging technologies targeting myeloperoxidase

256 s review, we describe the recent advances in molecular imaging technologies that have been specifical

257 expression of protein biomarkers in tumors, molecular-imaging technologies should ideally be capable

258 Clinicians want molecular imaging that-by being more reliable in tailori

259 We propose a molecular imaging TNM system (miTNM, version 1.0) as a s

260 and explores the potential for metabolic and molecular imaging to affect patient-level risk predictio

261 rapy targets and suggest future pathways for molecular imaging to contribute to this developing field

262 inical advances in the use of functional and molecular imaging to evaluate the tumor microenvironment

263 ancies may come from a better integration of molecular imaging to identify tumor subvolumes that may

264 We used translocator protein-targeted molecular imaging to obtain further insights into the ro

265 his study used nanoparticle-enhanced optical molecular imaging to probe in vivo mechanisms involving

266 Our work demonstrated a powerful molecular imaging tool that can be used for high resolut

267 This study validates a novel molecular imaging tool that enables the in vivo visualiz

268 tudies that may lead to a broadly applicable molecular imaging tool to examine abnormal tryptophan me

269 Radiolabeled molecular imaging tracers directed toward cellular targe

270 This first-in-human pilot study shows that molecular imaging using an intravenous fluorescent agent

271 ation identifies a clear path toward in vivo molecular imaging using benchtop XFCT techniques in conj

272 Molecular imaging using PET may be a promising option be

273 n-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with (68)Ga-labeled prost

274 Molecular imaging using positron emission tomography and

275 f moving organs and contrast agent kinetics, molecular imaging using targeted and genetically express

276 first-in-human clinical trial on ultrasound molecular imaging (USMI) in patients with breast and ova

277 biodistribution of Au-tripods favorable for molecular imaging was confirmed using small animal posit

278 Here, using optical molecular imaging, we demonstrate that the alarmin S100A

279 Using functional molecular imaging, we observe that navigation in virtual

280 1 expression by contrast-enhanced ultrasound molecular imaging were assessed.

281 Here we demonstrate a concept for molecular imaging which bypasses the need for convention

282 imaging modality has now shown potential for molecular imaging, which enables visualization of biolog

283 s disease using positron emission tomography molecular imaging with (11)C-IMA107, a highly selective

284 Molecular imaging with a lateral resolution of 75 nm and

285 Molecular imaging with anti-HER2 probes allows the nonin

286 for simultaneously volumetric structural and molecular imaging with cellular resolution in all three

287 These data indicate that molecular imaging with fluorescent antibodies has the po

288 Clearly, optical molecular imaging with fluorescently labeled antibodies

289 Molecular imaging with microbubbles targeted to the A1 d

290 Molecular imaging with PET is a rapidly emerging techniq

291 vivo, resulting in increased contrast during molecular imaging with PET.

292 mild conditions for eventual application in molecular imaging with positron emission tomography (PET

293 potential for preparing new radiotracers for molecular imaging with positron emission tomography.

294 Neuroimaging techniques such as molecular imaging with positron-emission tomography (PET

295 Molecular imaging with recently developed radiolabeled C

296 Molecular imaging with TCP-1 probes appears promising to

297 Molecular imaging with the PET tracer 3'-deoxy-3'-[(18)F

298 Molecular imaging with verapamil-PET identifies P-glycpr

299 is demonstrated and characterized for tissue molecular imaging, with a limit of detection in the rang

300 The use of targeted molecular imaging would help identify patients who will